Subscribe
shutterstock_2131359385_sruilk
9 November 2023BiotechnologyMarisa Woutersen

Taiwan company fails to overturn PTAB decision over eye treatment patent

Federal Circuit rejects appeal in patent dispute with California’s Cloudbreak Theraputics | Court stated failure to prove concrete injury.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis sues Regeneron over eye treatment
22 March 2018   Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea and Zaltrap.
Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Novartis sues Regeneron over eye treatment
22 March 2018   Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea and Zaltrap.
Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.

More on this story

Americas
Novartis sues Regeneron over eye treatment
22 March 2018   Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea and Zaltrap.
Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent